Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib

Mise à jour : Il y a 4 ans
Référence : NCT01564836

Femme et Homme

Extrait

This prospective study is performed to identify safer and more concrete indicators of successful discontinuation and explore contributing factors for sustained undetectable transcript


Critère d'inclusion

  • Chronic myeloid leukemia ,Imatinib ,Complete Molecular Response

Liens